bullish
Kintor Pharma (开拓药业) Pre-IPO: Interesting Prostate Cancer Drug but Low in Core Assets
523 Views03 Mar 2020 11:23
Kintor was founded by Chinese academic researchers returning from overseas. It has two main drugs, proxalutamide which targets prostate cancer and...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 8-minute read)
Discussions
(Paid Plans Only)
- Kintor Pharma (开拓药业) IPO: Weak in Cornerstone but Still Expect Upside12 May 2020
- Kintor Pharma (开拓药业) Pre-IPO: Post Hearing Updates and Efficacy of Reference Products03 May 2020
- Kintor Pharma (开拓药业) Pre-IPO: Thoughts on Valuation25 Mar 2020
- Kintor Pharma (开拓药业) Pre-IPO: Interesting Prostate Cancer Drug but Low in Core Assets03 Mar 2020
x